Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago

Granisetron

Anti-emetic drugs Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Nausea and Vomiting Cancer

Naurif Injection is used to prevent nausea and vomiting caused by cancer chemotherapy (including high-dose cisplatin regimens), both for the first course of treatment and repeat courses. It is also used to prevent and treat nausea and vomiting following surgery. Naurif Tablet is used to prevent nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin, as well as nausea and vomiting caused by radiation therapy, including total body irradiation and fractionated abdominal radiation.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Granisetron is a potent, selective antagonist of 5-HT3 receptors. It produces its antiemetic effect by blocking 5-HT3 receptors both centrally, in the medullary chemoreceptor zone, and peripherally, in the GI tract. Blocking these receptors in turn suppresses visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.

Pregnancy & Breastfeeding

Pregnancy category B. Studies in animals have shown no evidence of impaired fertility or harm to the fetus. Even so, this medicine should be used during pregnancy only if clearly needed. It is not known whether granisetron passes into human breast milk, so caution should be exercised when giving it to a nursing mother.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Granisetron Injection: For chemotherapy-induced nausea and vomiting in adults, the recommended dose is 10 mcg/kg given intravenously within 30 minutes before chemotherapy is started, and only on the day(s) chemotherapy is given. It may be given intravenously either undiluted over 30 seconds or diluted with 0.9% Sodium Chloride or 5% Dextrose and infused over 5 minutes. As a general precaution, Granisetron Injection should not be mixed in solution with other drugs. In pediatric patients 2 to 16 years of age, the recommended dose is also 10 mcg/kg; pediatric patients under 2 years of age have not been studied. In geriatric patients, renal failure patients, or hepatically impaired patients, no dosage adjustment is required. For the treatment of postoperative nausea and vomiting in adults, the recommended dose for prevention is a single 1 mg dose of Granisetron diluted to 5 ml and given as a slow intravenous injection over 30 seconds, with administration completed before induction of anesthesia. For treating nausea and vomiting that has already occurred after surgery, the recommended dose is 1 mg of Granisetron given undiluted, intravenously, over 30 seconds. The safety and effectiveness of Granisetron Injection for preventing or treating postoperative nausea or vomiting have not been established in pediatric patients. As with the chemotherapy indication, no dosage adjustment is required in geriatric patients, renal failure patients, or hepatically impaired patients. Granisetron Tablet: For emetogenic chemotherapy, the recommended adult oral dose is 2 mg once daily or 1 mg twice daily. With the 2 mg once-daily regimen, two 1 mg tablets are taken up to one hour before chemotherapy. With the 1 mg twice-daily regimen, the first 1 mg tablet is taken up to one hour before chemotherapy and the second tablet 12 hours after the first. Either regimen is used only on the day(s) chemotherapy is given, and no dosage adjustment is required for elderly, renal failure, or hepatically impaired patients. For radiation-induced nausea and vomiting, whether from total body irradiation or fractionated abdominal radiation, the recommended adult oral dose is 2 mg once daily, taken as two 1 mg tablets within one hour of irradiation. There is no experience with oral Granisetron for preventing radiation-induced nausea and vomiting in pediatric patients.